Isabella Abbasciano

Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.

G. Camussi, A. Barreca, L. Biancone, 2020, Clinical transplantation.

Hemodialysis arteriovenous fistula ligation after renal transplantation: Impact on graft resistive index

L. Biancone, F. Fop, Caterina Dolla, 2020, The journal of vascular access.

Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction

I. Deambrosis, A. Barreca, L. Biancone, 2020, PloS one.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Absence of IL-6 Receptor Blockade Effect on the Outcomes of Transplant Glomerulopathy in the Absence of Anti-HLA Donor-specific Antibodies

C. Caorsi, Caterina Dolla, A. Mella, 2024, Transplantation direct.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.